Syndax Pharma (SNDX) Stock Price, Quote & News

Company Profile

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a n...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 419 1400

Website: syndax.com

Address:

730 Third Avenue, 9th Floor, New York, United States

Night_Owl_Biotech Mar. 14 at 9:46 PM

Attached see $SNDX valuation, analyst revenue estimates & related multiples compared to $DAWN 's M&A exit valuation. If DAWN's market cap (post M&A announcement) is now 1.03X DAWN 5-year analyst consensus, would SNDX command a higher 5-year multiple than 1.03X in a hypothetical M&A exit (excluding cash/debt) because; 1. SNDX revenues generated higher gross profit margins than DAWN in FY2025 (SNDX 96% to DAWN 90%)? 2. SNDX revenues come from 2 FDA approved therapies compared to DAWN's 1 FDA approved therapy (in theory lowering risk to an acquirer)? 3. SNDX 2 products both appear to have longer patent lives (Niktimvo FY36, Revuforj 6/8/37) than DAWN's Ojemda (June 35)? We're only asking the question. This is not investment advice. $INCY $XBI $IBB

2 · Reply

JuggernautRaider Mar. 13 at 10:31 PM

$SLS it won’t take long. Bloomberg hosted a round table about the tens of billions of dollars in revenue which are coming off patent. SELLAS, $NUVB , $IMRX , $SNDX look like very compelling hematology/oncology buyout candidates ⏰

0 · Reply

Georgeson Mar. 12 at 5:42 PM

$SNDX Both sndx and kura are speaking at Barclays today. Let's see if they mentioned anything new, especially re Q1 sales.

0 · Reply

Georgeson Mar. 12 at 5:32 PM

$SNDX Maybe we will close green again by the end of the day? TACO.

0 · Reply

flanker30 Mar. 12 at 4:53 PM

$SNDX the only safe bet! I wish we get a BO here now, I so desperately want to move the profits from here to $TGTX and $IOVA

3 · Reply

LucilleDunn1998 Mar. 12 at 1:42 PM

$SNDX biotech momentum only matters with confirmation but the range is getting tight enough to watch

0 · Reply

WallStreetBuyDip Mar. 12 at 10:54 AM

$SNDX trading at $24.44, matching its highest level. Recent volume around 1.1M, calmer than 30 days back.

0 · Reply

dgbio Mar. 12 at 2:00 AM

$SNDX These are two different tracks. The moment you don't see another future except a buyout you lose. The company has to be successful as a stand-alone entity, doing everything they need: BD, fundraising, if needed, etc. Look at Day One (acquired two months after closing the Mersana deal). Look at Avidity (acquired right after a huge fundraising). When buyer comes you negotiate from strength. Read Avidity's proxy on negotiating with Novartis. It's a master-class from Sarah Boyce.

0 · Reply

Georgeson Mar. 12 at 1:25 AM

$SNDX Wut??!! Doesn't sound like they want the company to be sold off? "Syndax plans to in-license or acquire oncology products to expand its pipeline." "The company is exploring business development to expand its oncology pipeline."

2 · Reply

Georgeson Mar. 12 at 1:14 AM

$SNDX Syndax at Leerink Conference: Strategic Growth and Profitability On Wednesday, 11 March 2026, Syndax Pharmaceuticals (NASDAQ:SNDX) took center stage at the Leerink Global Healthcare Conference 2026. The company presented a strategic overview, highlighting robust sales growth for its drugs Revuforj and Niktimvo, while outlining plans for market expansion and a path to profitability. Despite challenges in a competitive landscape, Syndax remains optimistic about its financial and operational strategies. https://www.investing.com/news/transcripts/syndax-at-leerink-conference-strategic-growth-and-profitability-93CH-4555280

0 · Reply

Syndax Pharmaceuticals, Inc. (SNDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar 4, 2026, 4:01 PM EST - 11 days ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Feb 26, 2026, 10:47 PM EST - 16 days ago

Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 4:01 PM EST - 17 days ago

Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 23, 2026, 7:00 AM EST - 20 days ago

Syndax Announces Participation in March Investor Conferences

Feb 19, 2026, 7:00 AM EST - 24 days ago

Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026

Feb 12, 2026, 5:44 AM EST - 4 weeks ago

Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026

Feb 5, 2026, 7:00 AM EST - 5 weeks ago

Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit

Jan 13, 2026, 1:25 AM EST - 2 months ago

Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:00 AM EST - 2 months ago

Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 7:00 AM EST - 2 months ago

Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

Jan 5, 2026, 7:00 AM EST - 2 months ago

Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 8:15 AM EST - 3 months ago

Syndax Pharma: Continuing Execution In AML

Dec 12, 2025, 7:00 AM EST - 3 months ago

Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025

Dec 8, 2025, 6:47 PM EST - 3 months ago

Syndax Pharmaceuticals, Inc. (SNDX) Presents at The 67th American Society of Hematology (ASH) Annual Meeting Transcript

Dec 8, 2025, 6:50 AM EST - 3 months ago

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

Dec 1, 2025, 7:00 AM EST - 3 months ago

Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference

Nov 29, 2025, 10:08 PM EST - 3 months ago

Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth

Nov 10, 2025, 2:01 PM EST - 4 months ago

Syndax Pharmaceuticals, Inc. (SNDX) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 5, 2025, 11:57 AM EST - 4 months ago

Syndax Pharmaceuticals: Thesis Firing On All Cylinders, Sales Acceleration In 2026

Nov 3, 2025, 9:06 PM EST - 4 months ago

Syndax Pharmaceuticals, Inc. (SNDX) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 4:01 PM EST - 4 months ago

Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 3, 2025, 9:08 AM EST - 4 months ago

Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025

Nov 3, 2025, 9:08 AM EST - 4 months ago

Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025

Oct 30, 2025, 7:00 AM EDT - 4 months ago

Syndax Announces Participation in November Investor Conferences

Oct 27, 2025, 7:00 AM EDT - 4 months ago

Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025

Oct 26, 2025, 11:44 PM EDT - 4 months ago

Syndax Expands Revuforj Approval, Buy

$Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia Transcript$

Oct 24, 2025, 8:47 PM EDT - 5 months ago

Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia Transcript

$Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia$

Oct 24, 2025, 1:58 PM EDT - 5 months ago

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

Oct 15, 2025, 2:30 PM EDT - 5 months ago

3 Biotech Stocks I Am Accumulating

ADMA HRMY INCY XBI

Oct 9, 2025, 5:00 PM EDT - 5 months ago

Making Money In Biotech Stocks

GERN

Sep 19, 2025, 12:53 PM EDT - 6 months ago

3 Potential Biotech Acquisition Targets

AZN ETNB INCY MLYS TVTX

$Syndax's Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia$

Sep 19, 2025, 7:00 AM EDT - 6 months ago

Syndax's Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

Sep 10, 2025, 6:10 PM EDT - 6 months ago

Syndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRC

Sep 2, 2025, 7:50 PM EDT - 6 months ago

Syndax Pharmaceuticals, Inc. (SNDX) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 26, 2025, 7:00 AM EDT - 7 months ago

Syndax Announces Participation in September Investor Conferences

Aug 13, 2025, 6:34 PM EDT - 7 months ago

Syndax Pharmaceuticals: A Tale Of Two Drug Launches

Aug 5, 2025, 12:59 PM EDT - 7 months ago

Syndax Pharmaceuticals: The Story Brightens

Aug 4, 2025, 11:52 PM EDT - 7 months ago

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 4:01 PM EDT - 7 months ago

Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 28, 2025, 7:00 AM EDT - 8 months ago

Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025

Jul 8, 2025, 5:18 AM EDT - 8 months ago

Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals

$Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia$

Jun 24, 2025, 4:01 PM EDT - 9 months ago

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

Jun 12, 2025, 12:02 PM EDT - 9 months ago

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

$Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025$

Jun 12, 2025, 7:00 AM EDT - 9 months ago

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025

May 29, 2025, 7:00 AM EDT - 10 months ago

Syndax Announces Participation in June Investor Conferences

May 14, 2025, 9:30 AM EDT - 10 months ago

Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)

May 12, 2025, 4:01 PM EDT - 10 months ago

Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

May 8, 2025, 7:00 AM EDT - 11 months ago

Syndax Announces Participation in May Investor Conferences

$Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood$

May 7, 2025, 4:01 PM EDT - 11 months ago

Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood

Night_Owl_Biotech Mar. 14 at 9:46 PM

2 · Reply

JuggernautRaider Mar. 13 at 10:31 PM

0 · Reply

Georgeson Mar. 12 at 5:42 PM

$SNDX Both sndx and kura are speaking at Barclays today. Let's see if they mentioned anything new, especially re Q1 sales.

0 · Reply

Georgeson Mar. 12 at 5:32 PM

$SNDX Maybe we will close green again by the end of the day? TACO.

0 · Reply

flanker30 Mar. 12 at 4:53 PM

$SNDX the only safe bet! I wish we get a BO here now, I so desperately want to move the profits from here to $TGTX and $IOVA

3 · Reply

LucilleDunn1998 Mar. 12 at 1:42 PM

$SNDX biotech momentum only matters with confirmation but the range is getting tight enough to watch

0 · Reply

WallStreetBuyDip Mar. 12 at 10:54 AM

$SNDX trading at $24.44, matching its highest level. Recent volume around 1.1M, calmer than 30 days back.

0 · Reply

dgbio Mar. 12 at 2:00 AM

0 · Reply

Georgeson Mar. 12 at 1:25 AM

2 · Reply

Georgeson Mar. 12 at 1:14 AM

0 · Reply

Georgeson Mar. 11 at 6:41 PM

$SNDX Anybody listen into Leerink Global Healthcare Conference this morning?

1 · Reply

DragonAlgo Mar. 11 at 5:25 AM

🐉 $SNDX CALL — DragonAlgo® Signal Contract: SNDX CALL Expiry: 2026-04-17 | Strike: $25.00 | Type: CALL Option Plan (premium): Entry: $2.15 Stop: $1.55 TP1: $2.79 TP2: $3.65 TP3: $5.16 🔗 https://dragonalgo.com

0 · Reply

BillionerOfKing Mar. 11 at 3:29 AM

$SNDX Current Stock Price: $24.15 Contracts to trade: $24.0 SNDX Mar 20 2026 Call Entry: $0.65 Exit: $1.05 ROI: 61% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Georgeson Mar. 10 at 11:55 PM

$SNDX Does anybody know how many shares traded at $24.94? Current after hr quote: $24.94 +0.78 (+3.23%) Volume 68,513

0 · Reply

Alien1980 Mar. 10 at 8:27 PM

$SNDX just could not break out of Distribution Zone 1 PP 25.2 so I TP when the retracement cracked 25.09. Still almost 2 per share. Closed in local accumulation, but at this point, we must wait for confirmation...

1 · Reply